ADXS-HPV was well-tolerated and a maximum tolerated dose was established.

These "maximum tolerated doses" injure cells and tissues and set off reparative cell division.

The dosage used in the study was eight times greater than the so-called maximum tolerated dose, the amount above which tissue damage occurs even from innocent substances because of the high concentration.

They identified that the maximum tolerated dose of nintedanib is 20 0 mg when taken once a day.

In the first human study of BIBW 2992, the maximum tolerated dose in a two-week-on, two-week off schedule was 70 mg once-daily.

The goal was to find what Wilson calls "the maximum tolerated dose," one high enough to get the gene to work, but low enough to spare patients serious side effects.

The maximum tolerated dose was 5 mg/day for 2 days prior to chemotherapy and 10 mg/day for 7 days postchemotherapy.

The maximum tolerated dose for phase II studies was determined to be 300 mg/m/day since at a dose of 400 mg/m/day painful blisters developed on the patients hands and feet.

The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.

The maximum tolerated dose was observed to be an infusion of 0.5 mg/kg/h.